Patients with bioprosthetic aortic valve failure who underwent transcatheter aortic valve replacement had sustained improved hemodynamic status, favorable survival and excellent quality of life and functional outcomes at 3 years, according to a study published in the Journal of the American College of Cardiology.
John G. Webb, MD, director of interventional cardiology at St. Paul’s Hospital in Vancouver and professor in the division of cardiology at the University of British Columbia, and colleagues analyzed data from 365 patients (mean age, 79 years; 64% men) from the PARTNER 2 trial who had symptomatic severe dysfunction of a bioprosthesis who were eligible for valve-in-valve treatment with a transcatheter heart valve (Sapien XT, Edwards Lifesciences).
Read the full story on Healio News.
